PDCD1 and neoplasm: Our results showed that the tumor cell survival rate was significantly reduced with the combined anti-PD-1 antibody and C/H treatment, indicating that the anti-PD-1 antibody and C/H treatment enhanced CTL activity against 4T1 tumor cells (Figure 6B).